Given the benefits of antiretroviral treatment, for many individuals with HIV, substance use disorder - including opioid, alcohol, and tobacco use disorder - is a greater threat to their health than the virus. In collaboration with four partnering HIV clinics in the US northeast and in the context of the New England HIV Implementation Science Network, a group of Yale School of Medicine doctors led a randomized clinical trial to evaluate the impact of Implementation Facilitation, a package of implementation strategies (e.g., learning collaboration, external facilitation, education and academic detailing), to help clinicians and staff at these sites enhance provision of proven addiction treatments to their patients.
More from Yale School of Medicine
Published: Saturday, October 29, 2022
